Approval · Notice of Compliance 22188 · 2019
TECENTRIQ: Notice of Compliance 22188
Issued May 24, 2019
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 22188
- Date
- May 24, 2019
- Company
- Hoffmann-La Roche LimitedMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: tecentriq in combination with bevacizumab, paclitaxel and carboplatin for the first line treatment of adult patients with metastatic non-squamish non-small cell lung cancer (nsclc) with no egfr or alk genomic tumor aberrations and no prior systemic chemotherapy treatment for metastatic non-squamish nsclc
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TECENTRIQ | Not yet assigned | — |
Medicinal ingredients
- ATEZOLIZUMAB 60 MG per ML